| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Y Meltze. Role of serotonin in the action of atypical antipsychotic drugs. Clinical neuroscience (New York, N.Y.). vol 3. issue 2. 1995-11-29. PMID:7583621. |
clozapine is the first of a new generation of antipsychotic drugs which constitutes a major advance in the treatment of schizophrenia. |
1995-11-29 |
2023-08-12 |
Not clear |
| Y Levkovitch, J Kronenberg, N Kayser, M Zvyagelski, B Gaoni, N Gadot. Clozapine for tardive dyskinesia in adolescents. Brain & development. vol 17. issue 3. 1995-11-13. PMID:7573764. |
this report describes the beneficial effect of clozapine on tardive dyskinesia in two adolescents with schizophrenia. |
1995-11-13 |
2023-08-12 |
Not clear |
| D Pickar, J K Hsia. Clozapine treatment of schizophrenia. JAMA. vol 274. issue 12. 1995-10-17. PMID:7674530. |
clozapine treatment of schizophrenia. |
1995-10-17 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
clozapine and the treatment of schizophrenia. |
1995-09-26 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
clozapine, an atypical antipsychotic medication, is the most significant pharmacological advancement in the treatment of chronic schizophrenia in years. |
1995-09-26 |
2023-08-12 |
Not clear |
| P B Higgin. Clozapine and the treatment of schizophrenia. Health & social work. vol 20. issue 2. 1995-09-26. PMID:7649505. |
effective in treating the nearly 30 percent of people with schizophrenia who do not respond to conventional pharmacological and psychosocial therapies, clozapine offers new hope to many. |
1995-09-26 |
2023-08-12 |
Not clear |
| D Shore, S Matthews, J Cott, J A Lieberma. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophrenia bulletin. vol 21. issue 2. 1995-09-07. PMID:7543218. |
in september 1994, the national institute of mental health convened a group of scientists to discuss the clinical effects of rapid clozapine discontinuation, especially in light of the introduction of risperidone for the treatment of schizophrenia. |
1995-09-07 |
2023-08-12 |
Not clear |
| E R Lombertie, N Salome, P Villegier, F Laghrissi-Thode, F Nassi. [Arguments for early treatment of refractory schizophrenia]. L'Encephale. vol 21 Spec No 3. 1995-09-07. PMID:7628338. |
as such as quality of life and economy of health, it would be desirable to quickly think of alternatives neuroleptic's therapeutic protocols and clozapine in the treatment-resistant schizophrenias or those presenting an intolerance. |
1995-09-07 |
2023-08-12 |
Not clear |
| P Marti. [Medical economic impact of schizophrenia]. L'Encephale. vol 21 Spec No 3. 1995-09-07. PMID:7628346. |
although the acquisition cost of clozapine is high in comparison with that of standard antipsychotics, preliminary cost-effectiveness estimates in patients with treatment-resistant schizophrenia suggest that the clinical benefits of the drug (viz improved psychopathology; social functioning and quality of life) may confer medium to long term economic benefits, primarily by reducing the need for psychiatric hospital service. |
1995-09-07 |
2023-08-12 |
Not clear |
| Y Jin, S G Potkin, C Sandma. Clozapine increases EEG photic driving in clinical responders. Schizophrenia bulletin. vol 21. issue 2. 1995-09-07. PMID:7631173. |
photically driven electroencephalography was tested in 17 chronic schizophrenia patients who were treated with clozapine for 5 weeks. |
1995-09-07 |
2023-08-12 |
Not clear |
| J McEvoy, O Freudenreich, M McGee, C VanderZwaag, E Levin, J Ros. Clozapine decreases smoking in patients with chronic schizophrenia. Biological psychiatry. vol 37. issue 8. 1995-08-31. PMID:7619979. |
clozapine decreases smoking in patients with chronic schizophrenia. |
1995-08-31 |
2023-08-12 |
Not clear |
| V A Curtis, P Wright, A Reveley, R Kerwin, J V Luce. Effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. The British journal of psychiatry : the journal of mental science. vol 166. issue 5. 1995-08-31. PMID:7620750. |
effect of clozapine on d-fenfluramine-evoked neuroendocrine responses in schizophrenia and its relationship to clinical improvement. |
1995-08-31 |
2023-08-12 |
Not clear |
| W G Honer, G W MacEwan, L Kopala, S Altman, S Chisholm-Hay, K Singh, G N Smith, T Ehmann, S Ganesan, M Lan. A clinical study of clozapine treatment and predictors of response in a Canadian sample. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 40. issue 4. 1995-08-31. PMID:7621391. |
to study the clinical response to clozapine in patients with refractory schizophrenia. |
1995-08-31 |
2023-08-12 |
Not clear |
| H He, J S Richardso. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. International clinical psychopharmacology. vol 10. issue 1. 1995-08-30. PMID:7542676. |
although risperidone is effective in acute schizophrenia and in non-treatment-resistant schizophrenics, studies adequately comparing risperidone with clozapine in treatment-resistant schizophrenic patients remain to be published. |
1995-08-30 |
2023-08-12 |
human |
| L K Oyewumi, D J Freeman, D Vollic. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic drug monitoring. vol 17. issue 2. 1995-08-25. PMID:7624901. |
low-dose clozapine (25-75 mg every 12 h) was administered to 21 treatment-resistant patients with schizophrenia who had been split into three groups. |
1995-08-25 |
2023-08-12 |
Not clear |
| L K Oyewumi, D J Freeman, D Vollic. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic drug monitoring. vol 17. issue 2. 1995-08-25. PMID:7624901. |
these results suggest that individualized doses of clozapine for treatment-resistant patients with schizophrenia can be conveniently predicted from trough drug levels at the start of therapy. |
1995-08-25 |
2023-08-12 |
Not clear |
| M Weber, H Gerbe. [A high serum creatine kinase picture due to too much or too little exercise]. Deutsche medizinische Wochenschrift (1946). vol 120. issue 25-26. 1995-08-09. PMID:7600928. |
case 2 concerned a 28-year-old woman with paranoid schizophrenia who had taken several tablets of clozapine and then remained in bed for 3 days. |
1995-08-09 |
2023-08-12 |
Not clear |
| C J Schmidt, S M Sorensen, J H Kehne, A A Carr, M G Palfreyma. The role of 5-HT2A receptors in antipsychotic activity. Life sciences. vol 56. issue 25. 1995-07-24. PMID:7791509. |
in particular, the high affinity of clozapine for the 5ht2a receptor subtype has been suggested to contribute to its reduced side-effect liability, greater efficacy and its activity in therapy-resistant schizophrenia. |
1995-07-24 |
2023-08-12 |
Not clear |
| A Klimke, E Kliese. [The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects]. Fortschritte der Neurologie-Psychiatrie. vol 63. issue 5. 1995-07-20. PMID:7782019. |
for the use of clozapine in europe, it should be underlined that in 1992 the indication was restricted to "acute and chronic forms of schizophrenia" whereas formerly it was permitted to treat several other neuroleptic resistant syndromes with clozapine, e.g. |
1995-07-20 |
2023-08-12 |
Not clear |
| H Y Meltzer, J Kennedy, J Dai, M Parsa, D Rile. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 12. issue 1. 1995-07-05. PMID:7766285. |
the psychotic symptoms of the three patients studied responded to low doses of clozapine with plasma levels of clozapine between 4.5 and 16.1 ng/ml and n-desmethylclozapine between 2.6 and 6.1 ng/ml, much below the plasma clozapine levels usually found in clozapine-treated refractory schizophrenia or affective disorders (range 100 to 687 ng/ml). |
1995-07-05 |
2023-08-12 |
Not clear |